• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

共同 4RD 关于欧洲参考网络与产业合作的立场声明

Together4RD position statement on collaboration between European reference networks and industry.

机构信息

Newcastle University, Newcastle Upon Tyne, UK.

EURORDIS (Rare Diseases Europe), Paris, France.

出版信息

Orphanet J Rare Dis. 2023 Sep 5;18(1):272. doi: 10.1186/s13023-023-02853-9.

DOI:10.1186/s13023-023-02853-9
PMID:37670358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10478454/
Abstract

Notwithstanding two decades of policy and legislation in Europe, aimed to foster research and development in rare conditions, only 5-6% of rare diseases have dedicated treatments. Given with the huge number of conditions classed as rare (which is increasing all the time), this equates to major unmet need for patients (over 30 million in the EU alone). Worryingly, the pace of Research and Innovation in Europe is lagging behind other regions of the world, and a seismic shift in the way in which research is planned and delivered is required, in order to remain competitive and-most importantly-bring meaningful, disease-altering treatments to those who desperately need them. The European Reference Networks (ERNs), launched in 2017, hold major potential to alleviate many of these challenges, and more, but only if adequately supported (financially, technically, and via robust policies and infrastructure) to realise that potential: and even then, only if able to forge robust collaborations harnessing the expertise, resources, knowledge and data of all stakeholders involved in rare disease, including Industry. To-date, however, ERN-Industry interactions have been largely limited, for a range of reasons (concerning barriers both tangible and perceived). This Position Statement analyses these barriers, and explains how Together4RD is seeking to move the needle here, by learning from case studies, exploring frameworks for collaboration, and launching pilots to explore how best to plan and deliver multistakeholder interactions addressing real research needs.

摘要

尽管欧洲有二十年的政策和立法旨在促进罕见病的研究和开发,但只有 5-6%的罕见病有专门的治疗方法。考虑到被归类为罕见病的情况数量巨大(而且还在不断增加),这意味着患者有巨大的未满足需求(仅欧盟就有超过 3000 万人)。令人担忧的是,欧洲的研究和创新步伐落后于世界其他地区,需要彻底改变研究的规划和实施方式,以保持竞争力,最重要的是,为那些急需治疗的患者带来有意义的、改变疾病的治疗方法。欧洲参考网络(ERNs)于 2017 年推出,具有缓解许多这些挑战的巨大潜力,但前提是得到充分支持(在财务、技术方面,以及通过稳健的政策和基础设施)以实现这一潜力:即使如此,只有能够建立强大的合作关系,利用所有参与罕见病的利益相关者的专业知识、资源、知识和数据,包括工业界,才能实现这一目标。然而,迄今为止,由于各种原因(包括有形和感知的障碍),ERN 与工业界的互动在很大程度上受到限制。本立场声明分析了这些障碍,并解释了 Together4RD 如何通过从案例研究中学习、探索合作框架以及启动试点来探索如何最好地规划和实施多利益相关者互动来解决实际研究需求,从而在此方面取得进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6528/10478454/499f45177012/13023_2023_2853_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6528/10478454/aa8cf054301b/13023_2023_2853_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6528/10478454/49854fba4e35/13023_2023_2853_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6528/10478454/f7b9be94d969/13023_2023_2853_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6528/10478454/499f45177012/13023_2023_2853_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6528/10478454/aa8cf054301b/13023_2023_2853_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6528/10478454/49854fba4e35/13023_2023_2853_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6528/10478454/f7b9be94d969/13023_2023_2853_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6528/10478454/499f45177012/13023_2023_2853_Fig4_HTML.jpg

相似文献

1
Together4RD position statement on collaboration between European reference networks and industry.共同 4RD 关于欧洲参考网络与产业合作的立场声明
Orphanet J Rare Dis. 2023 Sep 5;18(1):272. doi: 10.1186/s13023-023-02853-9.
2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks.关于医疗保健专业人员、患者组织和行业在欧洲参考网络中作用的立场声明。
Orphanet J Rare Dis. 2016 Jan 25;11:7. doi: 10.1186/s13023-016-0383-5.
4
ERN BOND: The key European network leveraging diagnosis, research, and treatment for rare bone conditions.ERN BOND:利用诊断、研究和治疗罕见骨骼疾病的关键欧洲网络。
Eur J Med Genet. 2024 Apr;68:104916. doi: 10.1016/j.ejmg.2024.104916. Epub 2024 Feb 1.
5
The pooling of manpower and resources through the establishment of European reference networks and rare disease patient registries is a necessary area of collaboration for rare renal disorders.通过建立欧洲参考网络和罕见病患者登记处来集中人力和资源,是罕见肾脏疾病必要的合作领域。
Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv9-14. doi: 10.1093/ndt/gfu094.
6
RarERN Path: a methodology towards the optimisation of patients' care pathways in rare and complex diseases developed within the European Reference Networks.罕见病和复杂疾病欧洲参考网络优化患者护理路径的方法:RarERN路径
Orphanet J Rare Dis. 2020 Dec 14;15(1):347. doi: 10.1186/s13023-020-01631-1.
7
The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.欧洲罕见复杂结缔组织和肌肉骨骼疾病参考网络的附加值:ERN ReCONNET 成立后的前 5 年得到的启示。
Clin Exp Rheumatol. 2022 May;40 Suppl 134(5):3-11. doi: 10.55563/clinexprheumatol/d2qz38. Epub 2022 Mar 29.
8
European Reference Networks: challenges and opportunities.欧洲参考网络:挑战与机遇。
J Community Genet. 2021 Apr;12(2):217-229. doi: 10.1007/s12687-021-00521-8. Epub 2021 Mar 17.
9
Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective.镰状细胞病在欧盟的现状和挑战:欧洲罕见病网络-欧洲血液网的观点。
Lancet Haematol. 2023 Aug;10(8):e687-e694. doi: 10.1016/S2352-3026(23)00182-5. Epub 2023 Jul 11.
10
Telemedicine strategy of the European Reference Network ITHACA for the diagnosis and management of patients with rare developmental disorders.欧洲参考网络 ITHACA 用于罕见发育障碍患者诊断和管理的远程医疗策略。
Orphanet J Rare Dis. 2020 Apr 25;15(1):103. doi: 10.1186/s13023-020-1349-1.

引用本文的文献

1
Mapping the rare disease paediatric clinical trial availabilities in Europe.绘制欧洲罕见病儿科临床试验的可及情况。
Front Pediatr. 2025 May 19;13:1523847. doi: 10.3389/fped.2025.1523847. eCollection 2025.
2
The impact of rare diseases on the quality of life in paediatric patients: current status.罕见病对儿科患者生活质量的影响:现状
Front Public Health. 2025 Mar 24;13:1531583. doi: 10.3389/fpubh.2025.1531583. eCollection 2025.
3
The role of public health in rare diseases: hemophilia as an example.公共卫生在罕见病中的作用:以血友病为例。

本文引用的文献

1
Domain-Specific Common Data Elements for Rare Disease Registration: Conceptual Approach of a European Joint Initiative Toward Semantic Interoperability in Rare Disease Research.罕见病登记的特定领域通用数据元素:欧洲联合倡议在罕见病研究中实现语义互操作性的概念方法。
JMIR Med Inform. 2022 May 20;10(5):e32158. doi: 10.2196/32158.
2
Rare Disease Registries Are Key to Evidence-Based Personalized Medicine: Highlighting the European Experience.罕见病登记处是循证个体化医学的关键:突显欧洲经验。
Front Endocrinol (Lausanne). 2022 Mar 4;13:832063. doi: 10.3389/fendo.2022.832063. eCollection 2022.
3
Semantic modelling of common data elements for rare disease registries, and a prototype workflow for their deployment over registry data.
Front Public Health. 2025 Mar 20;13:1450625. doi: 10.3389/fpubh.2025.1450625. eCollection 2025.
4
Reframing risks in rare diseases: economics of networks, spillovers, and scale.重新审视罕见病的风险:网络、溢出效应和规模的经济学
Front Pharmacol. 2024 Dec 10;15:1516725. doi: 10.3389/fphar.2024.1516725. eCollection 2024.
5
Rare diseases: still on the fringes of universal health coverage in Europe.罕见病:在欧洲仍处于全民健康覆盖的边缘
Lancet Reg Health Eur. 2023 Dec 11;37:100783. doi: 10.1016/j.lanepe.2023.100783. eCollection 2024 Feb.
罕见病登记处常见数据元素的语义建模,以及在登记处数据上部署它们的原型工作流。
J Biomed Semantics. 2022 Mar 15;13(1):9. doi: 10.1186/s13326-022-00264-6.
4
Patients as Partners in Rare Disease Diagnosis and Research.患者是罕见病诊断和研究的伙伴。
Yale J Biol Med. 2021 Dec 29;94(4):687-692. eCollection 2021 Dec.
5
Rare diseases: past achievements and future prospects.罕见病:过去的成就与未来的前景
J Community Genet. 2021 Apr;12(2):205-206. doi: 10.1007/s12687-021-00529-0.
6
Our greatest untapped resource: our patients.我们最未被开发的资源:我们的患者。
J Community Genet. 2021 Apr;12(2):241-246. doi: 10.1007/s12687-021-00524-5. Epub 2021 Apr 21.
7
European Reference Networks: challenges and opportunities.欧洲参考网络:挑战与机遇。
J Community Genet. 2021 Apr;12(2):217-229. doi: 10.1007/s12687-021-00521-8. Epub 2021 Mar 17.
8
CPMS-improving patient care in Europe via virtual case discussions.CPMS 通过虚拟病例讨论改善欧洲的患者护理。
Endocrine. 2021 Mar;71(3):549-554. doi: 10.1007/s12020-021-02628-x. Epub 2021 Feb 2.
9
Policies and actions to tackle rare diseases at European level.欧洲层面解决罕见病的政策和行动。
Ann Ist Super Sanita. 2019 Jul-Sep;55(3):296-304. doi: 10.4415/ANN_19_03_17.
10
Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database.估算罕见病的累计点患病率:对孤儿药数据库的分析。
Eur J Hum Genet. 2020 Feb;28(2):165-173. doi: 10.1038/s41431-019-0508-0. Epub 2019 Sep 16.